BCYC.OQ
Latest Trade
27.60USDChange
0.62(+2.30%)Volume
2,031Today's Range
-
27.6052 Week Range
-
33.00As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 26.98 |
|---|---|
Open | 27.00 |
Volume | 2,031 |
3M AVG Volume | 1.92 |
Today's High | 27.60 |
Today's Low | 27.00 |
52 Week High | 33.00 |
52 Week Low | 10.26 |
Shares Out (MIL) | 21.30 |
Market Cap (MIL) | 570.97 |
Forward P/E | -11.78 |
Dividend (Yield %) | -- |
Bicycle Therapeutics Says BT7480 On Track For Phase I Trial Start In Second Half 2021
Bicycle Therapeutics Announces Settlement Of Patent Dispute With Pepscan Systems B.V.
Bicycle Therapeutics Files For ADSs Offering Of Up To $75 Million
Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.
Industry
Biotechnology & Drugs
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 48.29 |
Price To Book (MRQ) | 5.12 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 13.17 |
LT Debt To Equity (MRQ) | 13.17 |
Return on Investment (TTM) | -29.19 |
Return on Equity (TTM) | -26.55 |
* PHYSIOMICS PLC - CONFIRM THAT IT IS IN LATE STAGES OF AGREEING A CONTRACT WITH POTENTIAL NEW LARGE PHARMACEUTICAL CLIENT Source text for Eikon: Further company coverage:
* BICYCLE THERAPEUTICS FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2UeLZ4l) Further company coverage:
* BICYCLE THERAPEUTICS PLC - PHASE I DOSE ESCALATION COMPLETED FOR BT1718-RP2D ESTABLISHED AND PRELIMINARY SIGNS OF ANTI-TUMOR ACTIVITY OBSERVED
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.